Key clinical point: Low-dose recombinant interleukin-2 proved safe and effective for treatment of SLE in a randomized trial.
Major finding: The median SLEDAI score improved from 12 at baseline to 4 at week 24.
Study details: This randomized, double-blind, placebo-controlled clinical trial comprised 60 patients with SLE.
Disclosures: The presenter reported having no financial conflicts regarding her study.
Reporting from LUPUS 2019